Top

Breast Cancer

Published in:

01-07-2017 | Original Article

Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients

Authors: Zeinab Hallajian, Frouzandeh Mahjoubi, Nahid Nafissi

Published in: Breast Cancer | Issue 4/2017

Abstract

Background

DNA double-strand breaks (DSBs) as a serious lesion are repaired by non-homologous end-joining and homologous recombination pathways. ATM, BRCA1, RAD51 genes are involved in HR pathways. While some studies have revealed individual expression changes of these genes in different types of cancer, there are limited studies attempting to evaluate correlation of expression variations of these genes in breast cancer pathogenesis. This study aimed to determine RAD51, ATM and BRCA1 gene expression level and its association with clinicopathological factors in fresh breast cancer tissues. Moreover, this study evaluates potential correlations among expression levels of these genes.

Methods

50 breast cancer tissues were collected and examined for BRCA1, RAD51 and ATM gene expression by Real Time PCR. Expression changes were analyzed with REST software version 2009.

Results

mRNA expression was reduced in all these three genes when compared with β-Actin as a control gene (P _value < 0.001). Spearman’s test demonstrated a significant positive correlation among ATM, BRCA1 and RAD51 gene down expression (P _value < 0.0001). There was a significant association between down expression of ATM with stage (P _value < 0.05), necrosis (P _value < 0.05), perineural invasion (P _value < 0.05), vascular invasion (P _value < 0.01), malignancy (P _value ≤ 0.001), PR (P _value < 0.05) and ER status (P _value < 0.01). In addition, there was a significant association between down expression of BRCA1 with Ki67 (P _value ≤ 0.001). Moreover, there was a significant association between down expression of RAD51 with lymph node involvement (P _value < 0.01), auxiliary lymph node metastasis (P _value = 0.01), age (P = 0.001), grade (P _value < 0.05) and PR status (P _value < 0.05).

Conclusion

This study suggests association between expression changes in several DSB repair genes in a common functional pathway in breast cancer and the significant association between abnormal expression of these genes and important clinical prognostic factors.

Available only for authorised users

Single-Strand -DNA.

Loss of Heterozygosity.

Mendoza G, Portillo A, Olmos-Soto J. Accurate breast cancer diagnosis through real-time PCR her-2 gene quantification using immunohistochemically-identified biopsies. Oncol Lett. 2013;5(1):295–8.PubMed

Ralhan R, Kaur J, Kreienberg R, Wiesmüller L. Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett. 2007;248(1):1–17.CrossRefPubMed

Bunz F. DNA damage signaling downstream of ATM. Molecular Determinants of Radiation Response. Berlin: Springer; 2011. p. 35–52.CrossRef

Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, et al. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 2000;60(12):3299–304.PubMed

Henning W, Stürzbecher H-W. Homologous recombination and cell cycle checkpoints: rad51 in tumour progression and therapy resistance. Toxicology. 2003;193(1):91–109.CrossRefPubMed

Bau D-T, Mau Y-C, Shen C-Y. The role of BRCA1 in non-homologous end-joining. Cancer Lett. 2006;240(1):1–8.CrossRefPubMed

Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4(4):511–8.CrossRefPubMed

Söderlund K, Skoog L, Fornander T, Askmalm MS. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol. 2007;84(3):242–51.CrossRefPubMed

Human Protein Atlas 2016 [cited 2016 12.05]. Available from: http://www.proteinatlas.org.

10.

Lambert S, Lopez BS. Characterization of mammalian RAD51 double strand break repair using non-lethal dominant-negative forms. EMBO J. 2000;19(12):3090–9.CrossRefPubMedPubMedCentral

11.

Bueno R, Canevari R, Villacis R, Domingues MAC, Caldeira J, Rocha R, et al. ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas. Ann Oncol. 2014;25(1):69–75.CrossRefPubMed

12.

Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27(17):2501–6.CrossRefPubMed

13.

Guo X, Yang C, Qian X, Lei T, Li Y, Shen H, et al. Estrogen receptor α regulates ATM expression through miRNAs in breast cancer. Clin Cancer Res. 2013;19(18):4994–5002.CrossRefPubMedPubMedCentral

14.

Rondeau S, Vacher S, De Koning L, Briaux A, Schnitzler A, Chemlali W, et al. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. Br J Cancer. 2015;112(6):1059–66.CrossRefPubMedPubMedCentral

15.

Angele S, Jones C, Reis Filho J, Fulford L, Treilleux I, Lakhani S, et al. Expression of ATM, p53, and the MRE11–Rad50–NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast. J Clin Pathol. 2004;57(11):1179–84.CrossRefPubMedPubMedCentral

16.

Angèle S, Falconer A, Foster CS, Taniere P, Eeles RA, Hall J. ATM protein overexpression in prostate tumors. Am J Clin Pathol. 2004;121(2):231–6.CrossRefPubMed

17.

Ko JJ, Klimowicz AC, Jagdis A, Phan T, Laskin J, Lau HY, et al. ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent. Head Neck. 2016;38:E384–91.CrossRefPubMed

18.

Rio PG, Pernin D, Bay J-O, Albuisson E, Kwiatkowski F, De Latour M, et al. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int J Oncol. 1998;13(4):849–54.PubMed

19.

Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 2011;13(4):1.CrossRef

20.

Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005;65(23):10692–9.CrossRefPubMed

21.

Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res. 2005;65(24):11384–91.CrossRefPubMed

22.

Turner N, Reis-Filho J, Russell A, Springall R, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26(14):2126–32.CrossRefPubMed

23.

WU Jing-Jing CX, Xiong C. Clinical significance of BRCA1 and Ki-67 expression in breast cancer. Cancer Research and Clinic. 2014;26(1):1–5.

24.

Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3(5):279–90.CrossRefPubMedPubMedCentral

25.

Choi YE, Pan Y, Park E, Konstantinopoulos P, De S, D’Andrea A, et al. MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. Elife. 2014;3:e02445.PubMedPubMedCentral

26.

Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology. 2009;55(6):696–704.CrossRefPubMedPubMedCentral

27.

Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair. 2008;7(5):686–93.CrossRefPubMedPubMedCentral

28.

Wu M, Wang X, Mcgregor N, Pienta KJ, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol. 2014;85(6):866–76.CrossRefPubMedPubMedCentral

29.

Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Krüger S, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer. 2000;88(6):907–13.CrossRefPubMed

30.

Hu J, Wang N, Wang Y-J. XRCC3 and RAD51 expression are associated with clinical factors in breast cancer. PLoS One. 2013;8(8):e72104.CrossRefPubMedPubMedCentral

31.

Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci. 2014;111(12):4536–41.CrossRefPubMedPubMedCentral

32.

Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res. 2002;5(1):1.CrossRef

33.

Peluso S, Chiappetta G. High-mobility group A (HMGA) proteins and breast cancer. Breast Care. 2010;5(2):81–5.CrossRefPubMedPubMedCentral

34.

Wang A, Schneider-Broussard R, Kumar AP, MacLeod MC, Johnson DG. Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem. 2000;275(6):4532–6.CrossRefPubMed

35.

Gazy I, Zeevi DA, Renbaum P, Zeligson S, Eini L, Bashari D, et al. TODRA, a lncRNA at the RAD51 Locus, Is Oppositely Regulated to RAD51, and Enhances RAD51-Dependent DSB (Double Strand Break) Repair. PLoS One. 2015;10(7):e0134120.CrossRefPubMedPubMedCentral

36.

Berkovich E, Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene. 2003;22(2):161–7.CrossRefPubMed

37.

Lu J, Yang L, Tao Y, Sun L, Cao Y. Role of epidermal growth factor receptor in DNA damage repair. Chin Sci Bull. 2011;56(30):3132–7.CrossRef

38.

Chabalier-Taste C, Brichese L, Racca C, Canitrot Y, Calsou P, Larminat F. Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks. Oncotarget. 2016;7(3):2269.PubMedPubMedCentral

Title: Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients
Authors: Zeinab Hallajian
Frouzandeh Mahjoubi
Nahid Nafissi
Publication date: 01-07-2017
Publisher: Springer Japan
Published in: Breast Cancer / Issue 4/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-016-0750-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2017

Breast reconstruction and postmastectomy radiotherapy: complications by type and timing and other problems in radiation oncology

Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes

Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer

Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population

Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements

Keynote webinar | Spotlight on antibody–drug conjugates in cancer